Figure 6.

mRNA expression in peripheral CD14⁺ monocytes in healthy volunteers, standard care patients with infection, and intensive care patients with and without sepsis. (A) Expression of arachidonate 5-lipoxygenase-activating protein (ALOX5AP) mRNA in CD14⁺ monocytes from healthy volunteers, standard care patients with infection, and intensive care patients (left panel) or ICU patients with and without sepsis (right panel). (B) Longitudinal assessment of ALOX5AP mRNA expression in CD14⁺ monocytes from patients on day 1, 3, and 7 of the ICU stay. (C) Expression of monocytic guanine nucleotide exchange factor 10-like protein (ARHGEF10L) mRNA in CD14⁺ monocytes from healthy volunteers, standard care patients with infection, and intensive care patients (left panel) or ICU patients with and without sepsis (right panel). (D) Longitudinal assessment of ARHGEF10L mRNA expression in CD14⁺ monocytes from patients on day 1, 3, and 7 of the ICU stay. Statistics: * indicates p < 0.05, ** p < 0.01, and *** p < 0.001. For a comparison of two groups, the Mann–Whitney U test was used; for a comparison of more than two groups, the Kruskal–Wallis test was performed, followed by post hoc testing by Dunn’s multiple comparison test; and for longitudinal analysis (Figure 6B,D, right panels), two way ANOVA was performed, followed by a Bonferroni post-test. Sample sizes: healthy controls (HC) n = 54, standard care (SC) n = 42, intensive care unit (ICU) n = 76, no sepsis n = 40, and sepsis n = 36; no sepsis: d1 = 14, d3 = 10, and d7 = 6; sepsis: d1 = 16, d3 = 13, and d7 = 6.